# US 11,753,375 B2 · Crystalline psilacetin derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,753,375 B2
- Document ID: US11753375B2
- Status: Granted
- Kind: B2
- Application number: 17/906,212
- Filed: 2021-03-18
- Published: 2023-05-11
- Granted: 2023-09-12
- Earliest claimed: 2020-03-19
- Assignees: Caamtech, Inc.
- Applicants: Caamtech, Inc.
- Inventors: Andrew R. Chadeayne
- Web page: https://patentgrep.com/patent/US11753375B2

## CPC

- A61P 25/00: Drugs for disorders of the nervous system
- C07D 209/16: Tryptamines
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The disclosure relates to crystalline psilacetin derivatives, compositions containing those crystalline derivatives, and methods of treatment using them. The crystalline psilacetin derivatives include crystalline 4-acetoxy-N-methyl-N-ethyltryptammonium (4-AcO-MET) hydrofumarate (“crystalline 4-AcO-MET hy-drofumarate”), crystalline 4-acetoxy-N-methyl-N-allyltryptammonium (4-AcO-MALT) hydrofumarate (“crystalline 4-AcO-MALT hydrofumarate”), and crystalline 4-acetoxy-N,N-diallyltryptammonium (4-AcO-DALT) fumarate fumaric acid (“crystalline 4-AcO-DALT fumarate fumaric acid”).

## Claims

### Claim 1

A crystalline psilacetin derivative selected from the group consisting of crystalline 4-acetoxy-N-methyl-N-ethyltryptammonium (4-AcO-MET) hydrofumarate, crystalline 4-acetoxy-N-methyl-N-allyltryptammonium (4-AcO-MALT) hydrofumarate, and crystalline 4-acetoxy-N,N-diallyltryptammonium (4-AcO-DALT) fumarate fumaric acid.

### Claim 2 (depends on 1)

A composition comprising a crystalline psilacetin derivative according to claim 1 and an excipient.

### Claim 3 (depends on 1)

A composition comprising a crystalline psilacetin derivative according to claim 1 and a second component selected from (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) one or two purified cannabinoids and (d) a purified terpene.

### Claim 4 (depends on 1)

A method of treating a psychological disorder comprising the step of:
administering to a subject in need thereof a therapeutically effective amount of a crystalline psilacetin derivative according to claim 1.

### Claim 5 (depends on 2)

A method of treating a psychological disorder comprising the step of:
administering to a subject in need thereof a composition according to claim 2.

### Claim 6 (depends on 1)

A method of treating inflammation and/or pain comprising the step of:
administering to a subject in need thereof a therapeutically effective amount of a crystalline psilacetin derivative according to claim 1.

### Claim 7 (depends on 2)

A method of treating inflammation and/or pain comprising the step of:
administering to a subject in need thereof a composition according to claim 2.

### Claim 8 (depends on 3)

A method of treating a psychological disorder comprising the step of:
administering to a subject in need thereof a composition according to claim 3.

### Claim 9 (depends on 3)

A method of treating inflammation and/or pain comprising the step of:
administering to a subject in need thereof a composition according to claim 3.

### Claim 10 (depends on 2)

A composition of claim 2 wherein the crystalline psilacetin derivative is crystalline 4-acetoxy-N-methyl-N-ethyltryptammonium (4-AcO-MET) hydrofumarate.

### Claim 11 (depends on 2)

A composition of claim 2 wherein the crystalline psilacetin derivative is crystalline 4-acetoxy-N-methyl-N-allyltryptammonium (4-AcO-MALT) hydrofumarate.

### Claim 12 (depends on 2)

A composition of claim 2 wherein the crystalline psilacetin derivative is crystalline 4-acetoxy-N,N-diallyltryptammonium (4-AcO-DALT) fumarate fumaric acid.

### Claim 13 (depends on 3)

A composition of claim 3 wherein the crystalline psilacetin derivative is crystalline 4-acetoxy-N-methyl-N-ethyltryptammonium (4-AcO-MET) hydrofumarate.

### Claim 14 (depends on 3)

A composition of claim 3 wherein the crystalline psilacetin derivative is crystalline 4-acetoxy-N-methyl-N-allyltryptammonium (4-AcO-MALT) hydrofumarate.

### Claim 15 (depends on 3)

A composition of claim 3 wherein the crystalline psilacetin derivative is crystalline 4-acetoxy-N,N-diallyltryptammonium (4-AcO-DALT) fumarate fumaric acid.

### Claim 16 (depends on 1)

A crystalline psilacetin derivative of claim 1 wherein the crystalline psilacetin derivative is crystalline 4-acetoxy-N-methyl-N-ethyltryptammonium (4-AcO-MET) hydrofumarate characterized by:
a monoclinic, P21 crystal system space group at a temperature of about 200 K,
unit cell dimensions a=7.9555 (4) Å, b=13.3696 (7) Å, c=9.9708 (5) Å, and β=112.874 (2)°,
an XRPD having peaks at 11.7, 16.4, and 20.4°2θ±0.2°2θ, or
an XRPD pattern substantially similar to FIG. 4.

### Claim 17 (depends on 1)

A crystalline psilacetin derivative of claim 1 wherein the crystalline psilacetin derivative is crystalline 4-acetoxy-N-methyl-N-allyltryptammonium (4-AcO-MALT) hydrofumarate characterized by:
a monoclinic, P21 crystal system space group at a temperature of about 297 K,
unit cell dimensions a=7.9702 (4) Å, b=14.1788 (7) Å, c=9.8035 (5) Å, and β=113.394 (2)°,
an XRPD having peaks at 11.6, 15.9, and 17.5°2θ±0.2°2θ, or
an XRPD pattern substantially similar to FIG. 8.

### Claim 18 (depends on 1)

A crystalline psilacetin derivative of claim 1 wherein the crystalline psilacetin derivative is crystalline 4-acetoxy-N,N-diallyltryptammonium (4-AcO-DALT) fumarate fumaric acid characterized by:
a monoclinic, P2/c crystal system space group at a temperature of about 297 K,
unit cell dimensions a=23.6642 (19) Å, b=8.4204 (18) Å, c=23.4002 (18) Å, and β=111.614 (6)°,
an XRPD having peaks at 9.1, 14.7, and 19.9°2θ±0.2°2θ, or
an XRPD pattern substantially similar to FIG. 12.
